CN105535021A - 一种治疗眼睛疲劳的滴丸 - Google Patents
一种治疗眼睛疲劳的滴丸 Download PDFInfo
- Publication number
- CN105535021A CN105535021A CN201610042116.0A CN201610042116A CN105535021A CN 105535021 A CN105535021 A CN 105535021A CN 201610042116 A CN201610042116 A CN 201610042116A CN 105535021 A CN105535021 A CN 105535021A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- drop pill
- poloxamer
- chitosan
- glyceryl monostearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006187 pill Substances 0.000 title claims abstract description 78
- 208000003464 asthenopia Diseases 0.000 title abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 87
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 71
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 62
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229920001661 Chitosan Polymers 0.000 claims abstract description 51
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 44
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 44
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 44
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 40
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960000502 poloxamer Drugs 0.000 claims abstract description 34
- 229920001983 poloxamer Polymers 0.000 claims abstract description 34
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims abstract description 34
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 31
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 31
- 239000011709 vitamin E Substances 0.000 claims abstract description 31
- 229940046009 vitamin E Drugs 0.000 claims abstract description 31
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 30
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 29
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 29
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 29
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 29
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 29
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 29
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 29
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 29
- 239000011648 beta-carotene Substances 0.000 claims abstract description 29
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 29
- 229960002747 betacarotene Drugs 0.000 claims abstract description 29
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 29
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 29
- 239000010949 copper Substances 0.000 claims abstract description 29
- 229910052802 copper Inorganic materials 0.000 claims abstract description 29
- 239000011777 magnesium Substances 0.000 claims abstract description 29
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 29
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960002477 riboflavin Drugs 0.000 claims abstract description 29
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 29
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 29
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 29
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 29
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 29
- 239000011701 zinc Substances 0.000 claims abstract description 29
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 29
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 29
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 14
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 14
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 14
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 14
- 229960003495 thiamine Drugs 0.000 claims abstract description 14
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 14
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 14
- 239000011719 vitamin A Substances 0.000 claims abstract description 14
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 14
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 14
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 14
- 239000011710 vitamin D Substances 0.000 claims abstract description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 14
- 229940045997 vitamin a Drugs 0.000 claims abstract description 14
- 229940046008 vitamin d Drugs 0.000 claims abstract description 14
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 35
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 35
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 claims description 30
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 28
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 28
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 28
- 239000008158 vegetable oil Substances 0.000 claims description 28
- 239000012530 fluid Substances 0.000 claims description 26
- -1 phylloxanthin Chemical compound 0.000 claims description 26
- 229940080350 sodium stearate Drugs 0.000 claims description 24
- 244000173166 Pyrus ussuriensis Species 0.000 claims description 20
- 235000011572 Pyrus ussuriensis Nutrition 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 20
- 239000000194 fatty acid Substances 0.000 claims description 20
- 229930195729 fatty acid Natural products 0.000 claims description 20
- 150000004665 fatty acids Chemical class 0.000 claims description 20
- 229940083608 sodium hydroxide Drugs 0.000 claims description 16
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 15
- DPRNENKPXAZQBI-UHFFFAOYSA-N alpha-Vitamin A Natural products OCC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C DPRNENKPXAZQBI-UHFFFAOYSA-N 0.000 claims description 15
- 229960002061 ergocalciferol Drugs 0.000 claims description 15
- 235000001892 vitamin D2 Nutrition 0.000 claims description 15
- 239000011653 vitamin D2 Substances 0.000 claims description 15
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000002844 melting Methods 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 238000004806 packaging method and process Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 208000005494 xerophthalmia Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 claims description 4
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 claims description 4
- 235000012677 beetroot red Nutrition 0.000 claims description 4
- 239000001654 beetroot red Substances 0.000 claims description 4
- 235000002185 betanin Nutrition 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 3
- 208000001860 Eye Infections Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010025421 Macule Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 235000012680 lutein Nutrition 0.000 abstract 1
- 239000001656 lutein Substances 0.000 abstract 1
- 229960005375 lutein Drugs 0.000 abstract 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 abstract 1
- 239000010773 plant oil Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract 1
- 239000006196 drop Substances 0.000 description 64
- 239000000243 solution Substances 0.000 description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种用于治疗眼睛疲劳的滴丸。该滴丸包含维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6,维生素B12,铁,铜,锌,镁,烟酰胺,泛酸钙,磷酸氢钙,壳聚糖,表面活性剂,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物,氢氧化钠,植物油。本发明的滴丸具有缓释效果,能长期发挥作用,具有广泛的应用前景。
Description
技术领域
本发明属于医药领域,涉及一种治疗眼睛疲劳的滴丸。
背景技术
眼科疾病主要包括干眼症、白内障、青光眼、眼部感染性炎症、黄斑变性、视网膜病变等疾病。其中干眼症是指由于泪液的质或量的异常,或泪液的动力学异常引起的泪膜不稳定及眼表面损害,导致眼部不适等症状的一类疾病。环境污染、佩戴隐形眼镜、不卫生用眼、服用某些药物及年龄增长都可能引起干眼症。干眼症的临床表现为眼部干燥、异物感、畏光、视力模糊或视力波动等症状。根据近年来流行病学研究调查显示,10%~20%的人患有不同程度的干眼症。
目前,治疗眼科疾病的眼科药物剂型主要有滴眼剂、软膏剂、片剂和颗粒剂等。但是关于具有缓释效果的滴丸剂则比较少见。
滴丸剂具有如下一些特点:1、设备简单、操作方便、利于劳动保护,工艺周期短、生产率高;2、工艺条件易于控制,质量稳定,剂量准确,受热时间短,易氧化及具挥发性的药物溶于基质后,可增加其稳定性;3、基质容纳液态药物量大,故可使液态药物固化;4、用固体分散技术制备的滴丸具有吸收迅速、生物利用度高的特点。
发明内容
本发明的目的之一在于提供一种用于治疗眼睛疲劳的滴丸。所述滴丸保持药物活性成分稳定之外还具有缓释效果,能够使药物在体内长时间发挥作用。
本发明的目的之二在于提供上述滴丸的制备方法。
本发明的目的之三在于提供上述滴丸的用途。
为了实现上述目的,本发明采取了如下技术方案:
本发明提供了一种用于治疗眼科疾病的滴丸,所述滴丸包括以下组分:维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.1g-0.9g,表面活性剂4mg-36mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物1.5g-4.5g,氢氧化钠20mg-40mg,植物油;其中,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5。
优选地,所述滴丸包括以下组分:维生素维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,表面活性剂15mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物3g,氢氧化钠30mg,植物油;其中,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5。
进一步,所述表面活性剂选自以下组中的一种或几种:十二烷基硫酸钠、卵磷脂,甜菜碱、脂肪酸甘油酯、脂肪酸山梨坦,聚山梨酯。
本发明还提供了上述滴丸的制备方法,所述方法包括如下步骤:
(1)按照前面所述的滴丸配方准备相应重量的原料组分;
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为1.0-2.5mg/mL,pH值在3-6之间的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.0-2.0mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入表面活性剂,混匀,倾入料液槽中,保持温度50-60℃20min;
(5)将步骤(4)获得的混合液滴入0-20℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
本发明还提供了上述滴丸在治疗眼科疾病中的用途。
进一步,所述眼科疾病包括但不限于,干眼症、白内障、青光眼、眼部感染性炎症、黄斑变性、视网膜病。
本发明的优点和有效效果:
本发明公开的滴丸可以维持药物活性成分的稳定性。
本发明公开的滴丸具有缓释效果,可以使药物活性成分缓慢释放,长时间发挥作用。
具体实施方式
下面结合实施例对本发明作进一步详细的说明。以下实施例仅用于说明本发明而不用于限制本发明的范围。
实施例1滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.1g,脂肪酸山梨坦4mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物1.5g,氢氧化钠20mg,植物油若干;其中,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为1.0mg/mL,pH值为3的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.0mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度50℃20min;
(5)将步骤(4)获得的混合液滴入0℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例2滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.9g,脂肪酸山梨坦36mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物4.5g,氢氧化钠40mg,植物油;其中,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2.5mg/mL,pH值为6的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为2.0mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度60℃20min;
(5)将步骤(4)获得的混合液滴入20℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例3滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,脂肪酸山梨坦15mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物3g,氢氧化钠30mg,植物油;其中,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例4滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,脂肪酸山梨坦15mg,硬脂酸钠0.5g,氢氧化钠30mg,植物油。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例5滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,脂肪酸山梨坦15mg,泊洛沙姆1g,氢氧化钠30mg,植物油。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将泊洛沙姆、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例6滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,脂肪酸山梨坦15mg,单硬脂酸甘油酯1.5g,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5,氢氧化钠30mg,植物油。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例7滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,脂肪酸山梨坦15mg,甘油明胶、聚乙二醇8000和硬脂酸混和物3g,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为2:3:1,氢氧化钠30mg,植物油。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将甘油明胶、聚乙二醇8000、硬脂酸、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例8滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,脂肪酸山梨坦15mg,甘油明胶、单硬脂酸甘油酯、聚乙二醇6000和硬脂酸的混合物3g,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为1:1:1.5,氢氧化钠30mg,植物油。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将单硬脂酸甘油酯、聚乙二醇6000、硬脂酸、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例9滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物3g,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5,氢氧化钠30mg,植物油。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例10滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,大豆磷脂3g,胆固醇0.8g,脂肪酸山梨坦15mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物3g,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5,氢氧化钠30mg,植物油。
(2)将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙、大豆磷脂、胆固醇溶于无水乙醇中,将上述混合液置于薄膜蒸发器上,减压除去有机溶剂得脂质膜,将上述脂质膜溶于氯化钙和葡萄糖组成的溶液(其中,氯化钙浓度为0.5g/L,葡萄糖浓度为1g/L)中,获得脂质体溶液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的脂质体溶液加入到步骤(3)制备的所述熔融物中,同时加入脂肪酸山梨坦,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例11滴丸的制备
(1)按照下列比例准备原料:
维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,甜菜碱15mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物3g,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5,氢氧化钠30mg,植物油。
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为2mg/mL,pH值为4.5的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.5mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入甜菜碱,混匀,倾入料液槽中,保持温度55℃20min;
(5)将步骤(4)获得的混合液滴入10℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
实施例12滴丸外观的检测
按中国药典(2010版)的方法检测滴丸的光滑圆整率,结果见表1:
表1滴丸的光滑圆整率测定
组别 | 光滑圆整率(%) |
实施例3 | 99.54 |
实施例4 | 73.28 |
实施例5 | 71.57 |
实施例6 | 74.25 |
实施例7 | 98.04 |
实施例8 | 97.49 |
结果表明,本发明提供的滴丸符合中国药典(2010版)关于滴丸的规定。
实施例13滴丸缓释效果检测
试验动物:新西兰兔110只,体重2.1-2.8kg。
试验方法:将新西兰兔常规喂养1周,随机分为11组,每组10只。分别口服给药实施例1-11中的滴丸和21金维他片。用药量均为10mg/kg。给药后0.5、1、6、24、72h和1、2周自耳动脉取1ml,用高效液相色谱仪测定不同时间点血样中维生素E的浓度(μg/L),结果见表2所示。
表2维生素E浓度测定
时间 | 0.5h | 1h | 6h | 24h | 72h | 1周 | 2周 |
实施例1 | 4.52 | 12.09 | 5.47 | 2.94 | 0.97 | 0.23 | 0 |
实施例2 | 4.63 | 12.74 | 5.51 | 2.26 | 0.54 | 0.11 | 0 |
实施例3 | 4.26 | 10.24 | 6.72 | 3.47 | 1.51 | 0.87 | 0.39 |
实施例4 | 6.47 | 18.23 | 2.51 | 0.04 | 0 | 0 | 0 |
实施例5 | 6.33 | 17.95 | 2.32 | 0.11 | 0 | 0 | 0 |
实施例6 | 6.49 | 18.32 | 2.41 | 0 | 0 | 0 | 0 |
实施例7 | 5.42 | 14.02 | 4.95 | 2.23 | 0.81 | 0.12 | 0 |
实施例8 | 5.20 | 13.93 | 4.71 | 2.42 | 0.92 | 0.24 | 0 |
实施例9 | 7.46 | 15.13 | 3.76 | 1.02 | 0.01 | 0 | 0 |
实施例10 | 5.62 | 15.26 | 3.75 | 1.96 | 0.61 | 0.21 | 0 |
实施例11 | 4.94 | 13.12 | 5.05 | 2.96 | 0.97 | 0.21 | 0 |
21金维他片 | 10.25 | 16.47 | 0.14 | 0 | 0 | 0 | 0 |
由表2可见,本发明制备的部分滴丸具有良好的缓释效果。
实施例14滴丸治疗干眼病的效果
1、一般资料
收集80例干眼症患者,其中男40例,女40例,年龄21-56岁,病程1-3年。随机分为:治疗组40例,空白组40例。两组性别、年龄、病程等资料无显著性差异,具有可比性。
2、试验方法
2.1治疗方法
治疗组口服本发明按照具体实施例3制得的滴丸,每日1次。疗程1个月。
空白组口服安慰剂滴丸,每日1次。疗程1个月。
2.2观察项目:实验前后,眼睛干涩,容易疲倦,异物感,痛灼热感,分泌物粘稠,怕风,畏光,暂时性视力模糊等症状进行观察。
3、疗效标准与治疗结果
3.1疗效标准
痊愈:临床症状全部消失,半年内未见复发。
好转:临床症状减轻。
无效:临床症状无明显好转或加重。
3.2治疗统计结果见表3。
表3两组疗效比较
痊愈 | 好转 | 无效 | 有效率 | 治愈率 | |
治疗组 | 39 | 1 | 0 | 100% | 97.5% |
空白组 | 0 | 1 | 39 | 2.5% | 0 |
由表3统计结果可见,本发明制得的滴丸能够安全有效治疗干眼症,缓解眼睛疲劳。
上述实施例的说明只是用于理解本发明的方法及其核心思想。应当指出,对于本领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也将落入本发明权利要求的保护范围内。
Claims (6)
1.一种用于治疗眼科疾病的滴丸,其特征在于,所述滴丸包括以下组分:维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.1g-0.9g,表面活性剂4mg-36mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物1.5g-4.5g,氢氧化钠20mg-40mg,植物油;其中,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5。
2.根据权利要求1所述的滴丸,其特诊在于,所述滴丸包括以下组分:维生素A2000IU,β-胡萝卜素2mg,维生素D200IU,维生素E5mg,维生素B12.5mg,维生素B22.5mg,叶黄素2.5mg,维生素B60.25mg,维生素B120.5μg,铁5mg,铜0.5mg,锌0.25mg,镁0.5mg,烟酰胺7.5mg,泛酸钙2.5mg,磷酸氢钙279mg,壳聚糖0.4g,表面活性剂15mg,硬脂酸钠、泊洛沙姆和单硬脂酸甘油酯的混合物3g,氢氧化钠30mg,植物油;其中,硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯的比例为0.5:1:1.5。
3.根据权利要求2所述的滴丸,其特征在于,所述表面活性剂选自以下组中的一种或几种:十二烷基硫酸钠、卵磷脂,甜菜碱、脂肪酸甘油酯、脂肪酸山梨坦,聚山梨酯。
4.一种制备权利要求1-3中任一项所述的滴丸的方法,其特征在于,所述方法包括如下步骤:
(1)按照权利要求1-3中任一项所述的滴丸准备相应重量的原料组分;
(2)将壳聚糖溶解于质量分数为1.0%的醋酸溶液中,制成浓度为1.0-2.5mg/mL,pH值在3-6之间的壳聚糖溶液,将维生素A、β-胡萝卜素、维生素D、维生素E、维生素B1、维生素B2、叶黄素、维生素B6、维生素B12、铁、铜、锌、镁、烟酰胺、泛酸钙、磷酸氢钙溶于壳聚糖溶液中,再在25℃条件下按所需比例加入浓度为1.0-2.0mg/mL的三聚磷酸钠水溶液,充分搅拌获得混合液;
(3)将硬脂酸钠、泊洛沙姆、单硬脂酸甘油酯、氢氧化钠磨混合均匀,在水浴上加热熔融,并混匀,获得熔融物;
(4)将步骤(2)制备的混合液加入到步骤(3)制备的所述熔融物中,同时加入表面活性剂,混匀,倾入料液槽中,保持温度50-60℃20min;
(5)将步骤(4)获得的混合液滴入0-20℃的植物油中形成滴丸,吸除冷凝液,干燥滴丸,包装。
5.权利要求1-3中任一项所述的滴丸在制备治疗眼科疾病药物中的用途。
6.根据权利要求5所述的用途,其特征在于,所述眼科疾病包括干眼症、白内障、青光眼、眼部感染性炎症、黄斑变性、视网膜病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610042116.0A CN105535021A (zh) | 2016-01-22 | 2016-01-22 | 一种治疗眼睛疲劳的滴丸 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610042116.0A CN105535021A (zh) | 2016-01-22 | 2016-01-22 | 一种治疗眼睛疲劳的滴丸 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105535021A true CN105535021A (zh) | 2016-05-04 |
Family
ID=55814947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610042116.0A Pending CN105535021A (zh) | 2016-01-22 | 2016-01-22 | 一种治疗眼睛疲劳的滴丸 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105535021A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020115552A2 (en) | 2018-12-06 | 2020-06-11 | Lipicare Life Sciences Ltd. | Vitamin d micro-emulsions and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1695690A (zh) * | 2005-05-13 | 2005-11-16 | 天津大学 | 新型苏冰滴丸及制备方法 |
CN102325468A (zh) * | 2009-01-23 | 2012-01-18 | 惠氏有限责任公司 | 为50岁以上个体提高活力、免疫力、眼与骨骼健康的营养补充剂 |
-
2016
- 2016-01-22 CN CN201610042116.0A patent/CN105535021A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1695690A (zh) * | 2005-05-13 | 2005-11-16 | 天津大学 | 新型苏冰滴丸及制备方法 |
CN102325468A (zh) * | 2009-01-23 | 2012-01-18 | 惠氏有限责任公司 | 为50岁以上个体提高活力、免疫力、眼与骨骼健康的营养补充剂 |
Non-Patent Citations (2)
Title |
---|
张奇: "《军用药物制剂工程学》", 30 April 2012, 北京理工大学出版社 * |
高娴等: "离子凝胶法制备壳聚糖载药微囊", 《天津医科大学学报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020115552A2 (en) | 2018-12-06 | 2020-06-11 | Lipicare Life Sciences Ltd. | Vitamin d micro-emulsions and uses thereof |
EP3890746A4 (en) * | 2018-12-06 | 2022-08-10 | Lipicare Life Sciences Ltd. | VITAMIN D MICROEMULSIONS AND THEIR USES |
AU2019391397B2 (en) * | 2018-12-06 | 2023-06-15 | Lipicare Life Sciences Ltd. | Vitamin D micro-emulsions and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111840218B (zh) | 依达拉奉剂型 | |
DE60309433T2 (de) | Pharmazeutische zusammensetzungen für proteasehemmer für hepatitis-c-virus | |
CN101716214B (zh) | 含有蒲公英提取物的药物组合物及其制药用途和制备方法 | |
US10647669B2 (en) | Composition containing lutein/lutein ester and applications thereof | |
RU2761967C2 (ru) | Способ лечения, включающий пероральное или желудочное введение эдаравона | |
CN101564375A (zh) | 一种中药眼用即型凝胶 | |
US20230390213A1 (en) | Transdermal psychoactive alkaloid composition and preparation thereof | |
CN101653413B (zh) | 他克莫司眼用乳剂及其制备方法 | |
CN102143687A (zh) | 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途 | |
CN104337829B (zh) | 一瓶装脂微乳复合13种维生素冻干制剂 | |
RU2625797C2 (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
CN105535021A (zh) | 一种治疗眼睛疲劳的滴丸 | |
AU2015291529B2 (en) | Coix seed oil containing 13 glycerides, and pharmaceutical preparation and use thereof | |
US20210346471A1 (en) | Superoxide dismutase compositions and methods | |
CN103919718B (zh) | 一种维生素a棕榈酸酯滴眼剂及其制备方法和用途 | |
CN104161763B (zh) | 一种药物组合物作为制备治疗皮炎湿疹中的应用 | |
CN101584703A (zh) | 一种用于治疗阴道炎的药物组合物及其制备方法 | |
CN105560201A (zh) | 缓解眼睛疲劳的维生素缓释滴丸 | |
CN105012404B (zh) | 一种用于治疗干眼病的滴眼液及其制备方法 | |
CN102670501B (zh) | 可口服使用的维生素k1脂肪乳剂 | |
CN102370673A (zh) | 苏冰(速效救心)喷雾剂及其制备方法 | |
CN105147709A (zh) | 一种替诺福韦二吡呋酯或其药用盐的新用途 | |
CN104887642A (zh) | 一种盐酸林可霉素阴道泡腾片及制备方法 | |
CN111450054A (zh) | 一种含有咖啡酸酯的眼用制剂、制备方法及应用 | |
CN101491495A (zh) | 丹酚酸b镁注射剂、制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160504 |